Retatrutide is a synthetic peptide that acts simultaneously on GIP, GLP-1, and glucagon receptors. This triple mechanism influences the regulation of appetite, glucose metabolism, and energy expenditure.
Activity at the GLP-1 and GIP receptors is associated with reduced appetite and improved glycemic control, while the glucagon component may contribute to increased energy expenditure and the utilization of fat stores. In clinical trials, retatrutide has shown significant potential for reducing body weight and improving metabolic parameters.
Supplied as a lyophilized powder, it is intended strictly for laboratory research use only.
